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1006-l Percutaneous Left Atria1 Appendage Tranacatheter 
Occlusion (PLAATO) to Prevent Stroke in Patients With 
Atrial Fibrillation: First Human Experience 
mSievert, Michael D. Lesh, Thomas Trepels. Darrell Ogi, Lisa Goldman, Detlev 
Scherer, Cardiovasc. Center Bethanien. Frankfurt, Germany Univ. of CA San Francisco, 
San Francisco, California. 
Background: Warfarin is effective in reducing stroke in those patients with atrial fibrilla- 
tion. However, it has a narrow therapeutic range and is contraindicated in many. The left 
atrial appendage (LAA) is the source of thrombi in > 90%. Obliteration of the LAA may 
preventive cardioembolic complications. We report the 1st human experience with percu- 
taneous left atrial appendage transcatheter occlusion (PLAATO). 
Patients: PLAATO was attempted in 4 pts (66 - 74 yrs) with atria1 fibrillation, additional 
stroke risk factors, and contraindication to warfarin. 
Methods: PLAATO” system consists of a self-expanding cage covered with ePTFE 
delivered through a 12Fr transseptal sheath specially designed to access the LAA. Ani- 
mal studies have shown efficacy at sealing the LAA with complete encapsulation and 
endothelialization by 1 - 3 mos. The implant has not served as the nidus for new throm- 
bus. Angiography is used to determine the initial device diameter. However, one can col- 
lapse the implant and either reposition or remove and replace with a different size. 
Results: The 1st pt had complex LAA anatomy and the procedure was abandoned due 
to perforation during catheter manipulation, and without implantation. Pertcardiocentesis 
was performed without sequelae. In the others, the procedure was successful in occlud- 
ing the LAA. Devices with dia. of 16, 23 8 32 mm were ultimately implanted without com- 
plications, There were 4 successful retrievals to change implant size. Transesophageal 
echocardiography showed the device well seated. Follow up x-rays and echocardio- 
grams revealed stable implants. 
Conclusions: (1) Transcathster closure of the LAA is feasible: (2) a novel technology 
may offer an option for pts with AF who are not candidates for anticoagulation; (3) a clin- 
ical trial is needed to show the long term safety and efficacy in reducing stroke. 
1006-21 Percutaneous Intervention For Occlusive Subclavian 
Artery Disease 
sA. Felipe Navarro, Debabrata Mukherjee, Christopher Bajzer, Jay 
Yadav, The C/eve/and Clinic Foundation, Cleveland, Ohio. 
BACKGROUND: Subclavian artery disease has varied clinical manifestations. The tradi- 
tional management for symptomatic subclavian stenosis or occlusion has been surgical 
revascularization. More recently, percutaneous transluminal angioplasty with subsequent 
stem placement has gained prominence as an alternative treatment to surgery. However, 
there is limited data on procedural and follow up outcomes. 
METHODS AND RESULTS: We retrospectively analyzed our peripheral endovascular 
records from April 1992 to March 2001. The records of 69 patients (40 males: mean age 
62.2 years, range 40-61years) were reviewed. Nine of ths intervened upon subclavian 
arteries were occluded. A total number of 106 stems were placed. Primary stem deploy 
ment was successful in 105 (99.1%) interventions. The 3 most common indications for 
intervention included patency of inflow to the left internal mammary artery pre- or post- 
coronary artery bypass surgery 30 (33.7%) am7 claudication 21 (23.6%) and subclavian 
steal syndrome 17 (19.1%). Procedural complications occurred in 13 (14.6%) cases 
(pseudoaneurysmsJhematomas in 5; non-flow limiting dissections in 4; digital atheroem- 
boli in 1; brachial artery injury requiring surgical repair in 1; stent maldeployment in 2). 
There were no major complications (death, MI, CVA). 
Follow up consisted of clinical exam. blood pressure measurement in both arms. arterial 
duplex examinations or pulse volume recordings. Follow up records was available for 66 
patients. This included 27 patients who were followed for a period between 12 and 54 
months after the initial intervention. Clinical evidence of restenosis occurred in 6 (6.9%) 
patients. In 1 of these patients, surgical intervention at 2 months was required. Two other 
patients underwent repeat stenting 23 and 21 months after therr rnrtral procedure. 
CONCLUSIONS: Percutaneous angioplasty and stenting of the subclavian artery is safe 
and effective. Excellent procedural outcomes as well as short and mid term patency 
results make it a reasonable alternative to surgical bypass procedures, however there is 
still need for investigation into long-tan patency rates. 
1006-22 Renal Stenting Preserves Single Kidney GFR Compared 
to Medical Therapy in Patlenta Wlth Renal Artery 
Stenosis: Fourteen-Month Follow-Up 
Daniel Soffer, Greoorv G. Pellirzpa, Daniel T. Lee, Oliver Wang, Helena Balon, Mary 
Valko, Judith A. Boura, Simon R. Dixon, William W. D’Neill. Robert D. Safian, William 
Beaumont Hospital, Royal Oak, Michigan. 
Background: Studies of renal stenting (RS) for preservation of renal function have 
yielded conflicting results, which may be related to the usa of serum creatinine as the 
sole measure of renal function. Renal scintigraphy with lothalamata and Tc-DTPA pro- 
vide a more accurate measure of total and single kidney GFR (SK-GFR). We determined 
the effect of RS on SK-GFR compared to medical therapy in pts with renal artery stenosis 
(RAS). Methods: We prospectively followed 41 pts with confirmed RAS. Total and SK- 
GFR ware measured in each patient at baseline and at 14 * 6 months of follow-up. Thir- 
teen Pts underwent RS (Grp I), while 26 pts ware treated medically, (Grp II). 
Rssultsz Baseline total and SK-GFR did not differ between the two groups. Follow-up 
scintigraphy demonstrated a mild reduction in total GFR in both groups (0.3% vs 6%, in 
Grp I vs. II respectively, p=NS). In contrast, SK-GFR improved in the stanotic kidney in 
Grp I pts, whereas it decreased in Grp II pts, (2.1 * 1.4 vs -4.9 f 1.2 ml/min/1.73m2, 
p=O.O024). The % change in SK-GFR at 14-months is shown below (Grp I increased by 
11 f 4% vs. Grp II decreased by 14 * 5%. p=O.O03). 
Conclusions: RS preserves SK-GFR in pts with RAS. whereas progressive deteriora- 
tion is observed in medically treated pts. Our findings suggest that RS should be consid- 
ered in pts with RAS to preserve renal function. 
- Grp I = Grp II 
P-oJw.9 
1006-23 Interventional Treatment of Different Localization of 
Inflammatory Vaaculitia: Takeyaau’a Arteritia 
Tae-Hoon Ahn, Eak_Kvun, Minsoo Son, Dong-Hoon Choi, Won-Heum Shim, Heart 
Center, Gachon Universi~ Inchecn, South Korea. 
Background: Although the initial reports demonstrated high procedural success rate of 
balloon PTA in patients with Takayasu’s arteritis the suboptimal results and rsstenosis 
will be the main limitations of balloon PTA. Stenting has some benefits for elastic recoil of 
the fibrotic vessels and restenosis as in other large vessels in Takayasu’s arteritis or ath- 
erosclerosis. Methods: We report the procedural outcomes of stenting and/or cutting bal- 
loon angioplasty for the stenosis of different localization of Takayasu’s arteritis underwent 
PTA with stems, and cutting balloon angioplasty and rotational atherectomy with stems 
for the hard fibrotic stenosis in carotid, vertebral, innominate, subclavian, renal, aorta, 
and coronary arteries. Results: Among the 14 patients there were 12 female and 2 male 
with a mean age of 36(17-66)years. Carotid stenting was performed in five patients, ver- 
tebral angioplasty and stenting in three patients, subclavian angioplasty and stenting in 
two patients, innominate stenting in one patient, renal angioplasty and stentfng in three 
patients, aortic angioplasty and stentfng in two patients and coronary stenting in four 
patients including two aorta-left main ostial, two left anterior descending, two right coro- 
nary and one left circumflex lesion(s). Patients who were diagnosed to have an active 
phase of ths disease received steroid, aspirin and ticlopidine for stenting prior to proce- 
dure. The procedural success was achieved in all patients. During the follow up ravascu- 
larization was performed in 20% for carotid, 33% for renal, 70% for coronary artery 
stenosis. 
Conclusions: PTA with stem implatation is a safe and feasible revascularization strategy 
for relief of stanotic in patients with Takayasu’s arteritis. However relatively small artery 
stenting such as coronary artery revealed high rate of restenosis necessitating the repeat 
revasculqarfzation. 
1006-24 Emergent IABP Insertion in Patients With Severe 
Aortolllac Dlaeaee and Acute Coronary Syndrome: Role 
of Bilateral Mac PTA +/- Stenting Preceding IABP 
David, Cardiovascular institute of the South, Lafayeffe, Louisiana. 
Background: Severe bilateral aortoitiac occlusive disease (BAIOD) has been consid- 
ered a contraindication for intraaortic balloon pump (IABP) insertion due to the high risk 
of vascular complications, We report 52 patients with BAIOD presenting with acute coro- 
nary syndrome (ACS) and cardiogenic shock (systolic BP <90 mm Hg) and a strategy of 
urgent coronary and peripheral angiography, bilateral iliac artery percutaneous translumi- 
nal angioplasty (PTA) +I- stenting. and immediate IABP insertion was used. 
Methods: Of 1004 IABPs placed between 1993-2000, 52 cases presented with simulta- 
neous EAIOD. ACS, and cardiogenic shock requiring emergent IABP insertion for hemo- 
dynamic stabilization and coronary revascularization. Definitive cardiac treatment 
required 34 PTCAs and 16 CABGs. All 52 patients required bilateral iliac artery interven- 
tion [47/52 (90%) PTAIstent, 5/52 (9.6%) PTA], successful IABP insertion, and definitive 
coronary revascularization. Iliac interventions required c7Occ contrast and no iliac inter- 
ventions required ~25 min. 
Results: 49/52 (94%) no vascular complications, l/52 (1.9%) simple surgical embolec- 
tomy, and 2l52 (3.6%) had minor hematomas. 30 day mortality 7152 (13%); 24.month 
mortality- 12f52 (23%). Overall mean follow up of 36 months, 315 patients treated with 
iliac PTA alone required PTA/stenting and 5147 (10.6%) originally treated with PTA&ant 
required additional PTAlstenting. 
Conclusion: In patients presenting with simultaneous BAIOD and ACS, iliac PTA +I- 
stenting is feasible, allows urgent IABP insertion for hemodynamic stabilization and 
definitive cardiac treatment and is a compelling reason for cardiologists to acquire skills 
in treating both CAD and PVD. BAIOD should not be considered an absolute contraindi- 
cation for IABP insertion. 
